D. Ross Camidge, University of Colorado Cancer Center (IMAGE)

University of Colorado Anschutz Medical Campus

D. Ross Camidge, University of Colorado Cancer Center

Caption

D. Ross Camidge, M.D., Ph.D., and colleagues show benefit of brigatinib as second-line therapy against ALK-positive lung cancer.

Credit

University of Colorado Cancer Center

Usage Restrictions

With attribution

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.